enprofylline has been researched along with Airflow Obstruction, Chronic in 1 studies
enprofylline : Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition, we assessed the risk of adverse events by normalising data on safety as a function of person-weeks." | 2.58 | Efficacy and safety profile of xanthines in COPD: a network meta-analysis. ( Barnes, PJ; Calzetta, L; Cazzola, M; Criner, GJ; Gabriella Matera, M; Martinez, FJ; Papi, A, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cazzola, M | 1 |
| Calzetta, L | 1 |
| Barnes, PJ | 1 |
| Criner, GJ | 1 |
| Martinez, FJ | 1 |
| Papi, A | 1 |
| Gabriella Matera, M | 1 |
1 review available for enprofylline and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Efficacy and safety profile of xanthines in COPD: a network meta-analysis.
Topics: Bronchodilator Agents; Forced Expiratory Volume; Humans; Lung; Pulmonary Disease, Chronic Obstructiv | 2018 |